Regional Intestinal Drug Absorption : Biopharmaceutics and Drug Formulation

The gastrointestinal tract (GIT) can be broadly divided into several regions: the stomach, the small intestine (which is subdivided to duodenum, jejunum, and ileum), and the colon. The conditions and environment in each of these segments, and even within the segment, are dependent on many factors, e...

Full description

Saved in:
Bibliographic Details
HerausgeberIn:
Sonstige:
Year of Publication:2022
Language:English
Physical Description:1 electronic resource (238 p.)
Tags: Add Tag
No Tags, Be the first to tag this record!
LEADER 05347nam-a2201249z--4500
001 993544724004498
005 20231214133246.0
006 m o d
007 cr|mn|---annan
008 202205s2022 xx |||||o ||| 0|eng d
035 |a (CKB)5680000000037755 
035 |a (oapen)https://directory.doabooks.org/handle/20.500.12854/81051 
035 |a (EXLCZ)995680000000037755 
041 0 |a eng 
100 1 |a Gonzalez-Alvarez, Maria Isabel  |4 edt 
245 1 0 |a Regional Intestinal Drug Absorption  |b Biopharmaceutics and Drug Formulation 
246 |a Regional Intestinal Drug Absorption  
260 |a Basel  |b MDPI - Multidisciplinary Digital Publishing Institute  |c 2022 
300 |a 1 electronic resource (238 p.) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
520 |a The gastrointestinal tract (GIT) can be broadly divided into several regions: the stomach, the small intestine (which is subdivided to duodenum, jejunum, and ileum), and the colon. The conditions and environment in each of these segments, and even within the segment, are dependent on many factors, e.g., the surrounding pH, fluid composition, transporters expression, metabolic enzymes activity, tight junction resistance, different morphology along the GIT, variable intestinal mucosal cell differentiation, changes in drug concentration (in cases of carrier-mediated transport), thickness and types of mucus, and resident microflora. Each of these variables, alone or in combination with others, can fundamentally alter the solubility/dissolution, the intestinal permeability, and the overall absorption of various drugs. This is the underlying mechanistic basis of regional-dependent intestinal drug absorption, which has led to many attempts to deliver drugs to specific regions throughout the GIT, aiming to optimize drug absorption, bioavailability, pharmacokinetics, and/or pharmacodynamics. In the book "Regional Intestinal Drug Absorption: Biopharmaceutics and Drug Formulation" we aim to highlight the current progress and to provide an overview of the latest developments in the field of regional-dependent intestinal drug absorption and delivery, as well as pointing out the unmet needs of the field. 
546 |a English 
650 7 |a Medicine  |2 bicssc 
650 7 |a Pharmaceutical industries  |2 bicssc 
653 |a bioequivalence 
653 |a Biopharmaceutics Classification System 
653 |a in vitro 
653 |a dissolution test 
653 |a pravastatin 
653 |a oral absorption 
653 |a in silico modeling 
653 |a GastroPlus 
653 |a Phoenix WinNonlin 
653 |a pharmacokinetics 
653 |a clinical studies 
653 |a ibuprofen 
653 |a manometry 
653 |a gastrointestinal 
653 |a mechanistic modeling 
653 |a PBPK 
653 |a PBBM 
653 |a disintegration 
653 |a dissolution 
653 |a enteric-coated 
653 |a ICH 
653 |a quality control 
653 |a regional intestinal permeability 
653 |a permeation enhancers 
653 |a absorption-modifying excipients 
653 |a oral peptide delivery 
653 |a intestinal perfusion 
653 |a pharmaceutical development 
653 |a controlled release drug product 
653 |a biopharmaceutics classification system 
653 |a drug solubility 
653 |a drug permeability 
653 |a location-dependent absorption 
653 |a segregated flow intestinal model (SFM) 
653 |a traditional model (TM) 
653 |a route-dependent intestinal metabolism 
653 |a first-pass effect 
653 |a drug-drug interactions 
653 |a DDI 
653 |a in vitro in vivo extrapolations 
653 |a IVIVE 
653 |a zero-order absorption 
653 |a first-order absorption 
653 |a combined zero- and first-order absorption 
653 |a transit compartment absorption model 
653 |a in situ perfusion 
653 |a microdevices 
653 |a shape 
653 |a mucoadhesion 
653 |a colon absorption 
653 |a nutrient digestion 
653 |a nutrient absorption 
653 |a gastrointestinal hormone 
653 |a postprandial glycaemia 
653 |a energy intake 
653 |a region of the gut 
653 |a obesity 
653 |a type 2 diabetes 
653 |a Franz–PAMPA 
653 |a BCS drugs 
653 |a biomimetic membrane 
653 |a Franz cell 
653 |a passive drug transport 
653 |a BCS class IV drugs 
653 |a segmental-dependent intestinal permeability 
653 |a intestinal absorption 
653 |a oral drug delivery 
653 |a biopharmaceutics 
653 |a physiologically-based pharmacokinetic (PBPK) modeling 
653 |a furosemide 
653 |a intestinal permeability 
653 |a human colon carcinoma cell layer (Caco-2) 
653 |a hierarchical support vector regression (HSVR) 
653 |a drug absorption 
653 |a drug solubility/dissolution 
653 |a regional/segmental-dependent permeability and absorption 
776 |z 3-0365-3658-2 
776 |z 3-0365-3657-4 
700 1 |a Dahan, Arik  |4 edt 
700 1 |a Gonzalez-Alvarez, Maria Isabel  |4 oth 
700 1 |a Dahan, Arik  |4 oth 
906 |a BOOK 
ADM |b 2023-12-15 05:48:14 Europe/Vienna  |f system  |c marc21  |a 2022-05-14 21:41:54 Europe/Vienna  |g false 
AVE |i DOAB Directory of Open Access Books  |P DOAB Directory of Open Access Books  |x https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5337739760004498&Force_direct=true  |Z 5337739760004498  |b Available  |8 5337739760004498